Article in HLA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Sudan TaoInstitute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.ORCID 0000-0003-3865-2250
Xuan YouInstitute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.
Paul J NormanDepartment of Biomedical Informatics and Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Katherine M KichulaDepartment of Biomedical Informatics and Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Lina DongInstitute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.ORCID 0000-0002-6791-7871
Nanying ChenInstitute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.
Ji HeInstitute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.
Wei ZhangInstitute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.
Faming ZhuInstitute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.ORCID 0000-0002-1963-9176
Funding
Evolution and Function of Immunogenetic Diversity across the Eastern HemisphereR01AI151549 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Paul John Norman · 2022 to 2026
$3.9M
Natural Killer cells and the Immunogenetics of COVID-19R01AI158410 · NIAID · UNIVERSITY OF COLORADO DENVER · PI NORMAN, PAUL JOHN · 2021 to 2024
$2.9M
National Science Foundation of China 82200258NIAID NIH HHS R01 AI151549NIAID NIH HHS R01 AI158410NIH HHS R01 AI158410Science Research Foundation of Zhejiang Healthy Bureau 2022KY139Science Research Foundation of Zhejiang Healthy Bureau 2024KY941Zhejiang Provincial Natural Science Foundation of China LGF22H080004
6 · The paper itself
Abstract
Killer-cell immunoglobulin-like receptor (KIR) interactions with HLA class I have crucial roles in modulating NK cell function in response to viral infections. To explore the correlation between KIR/HLA and susceptibility to SARS-CoV-2 infection, we analysed polymorphism of KIR genes, haplotypes, HLA allotypes, and the interplay between KIR and HLA in individuals diagnosed with COVID-19. Compared to a population control group, we observed a significantly increased frequency of KIR3DL3*00802 in the COVID-19 group. When encoded by the HLA-B gene, the frequency of HLA-Bw4, a ligand for KIR3DL1, was at lower frequency in the COVID-19 group. Additionally, significantly elevated frequencies of KIR-Bx3, KIR3DL3*00301, 3DL3*048, and C1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Analysis of KIR and HLA Polymorphism in Chinese Individuals With COVID-19. · full record | OpenQuestion